A Study of TAS2940 in Participants With Locally Advanced or Metastatic Solid Tumor Cancer

Study summary

This is a first-in-human, open label, multicenter study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and the preliminary antitumor activity of TAS2940 in patients with advanced or metastatic solid tumors who are not candidates for approved or available therapies.

Ask AI to explain this study

Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedTAS2940 and TAS2940

The study team can explain what participation involves.

Who it may be forNon-small cell lung cancer (NSCLC) · Locally advanced · Metastatic or stage IV

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Oct 14, 2025 · Source: ClinicalTrials.gov

Is enrollment open?Terminated

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 1

Interventional

Where is it offered?3 U.S. locations

Locations may change over time.

Who runs it?Taiho Oncology, Inc.

Study sponsor

Study overview

What this study is about

Purpose: Treatment
Study type: Interventional
Phase: Phase 1
Sponsor: Taiho Oncology, Inc.
Interventions being studied: Drug: TAS2940; Drug: TAS2940

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type

Non-small cell lung cancer (NSCLC)→

Disease setting

Locally advanced→Metastatic or stage IV→

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

Have histologically confirmed solid cancer that is locally advanced and metastatic and available standard treatment options have been exhausted
Have adequate organ function
ECOG PS 0-1 Dose Escalation:
Have measurable or non- measurable disease per RECIST criteria v1.1 or RANO
Any solid tumor with EGFR and / or HER2 aberration Dose Expansion:
Have measurable disease per RECIST criteria v1.1 for solid tumor (excluding primary brain tumor) or RANO (for glioblastoma)
Cohort A: Non-small cell lung cancer (NSCLC)
Cohort B: HER2 positive breast cancer
Cohort C: Recurrent or refractory glioblastoma
Cohort D: Other solid tumors with EGFR or HER2 aberrations

Reasons someone may not be able to joinExclusion criteria

Non-stable brain metastases
Have significant cardiovascular disorder
Have not recovered from prior cancer treatment
A serious illness or medical condition

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

Tennessee OncologyNashville, Tennessee
University of Texas MD Anderson Cancer CenterHouston, Texas
CLCC Gustave RoussyVillejuif, Cedex

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Oct 14, 2025. Always confirm current availability with the study team.

View original record ↗